• Vicapsys Life Sciences signed a definitive agreement to acquire FDA-approved NitroMist nitroglycerin lingual aerosol for a US$ 2 million convertible note.
• Preparations for the product’s relaunch include stability, medium-fill and pre-production batches with a contract manufacturing partner.
• The company is also in talks to acquire a roughly 120,000-square-foot former pharmaceutical manufacturing facility in Puerto Rico.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicapsys Life Sciences Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.